Similar articles

• Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.

  Iacob S, Gheorghe L, Hrehoret D, Becheanu G, Herlea V, Popescu I. Iacob S, et al. J Gastrointestin Liver Dis. 2008 Jun;17(2):165-72. J Gastrointestin Liver Dis. 2008. PMID: 18568137
• An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.

  Massoumi H, Elsiesy H, Khaitova V, Peterson B, Norkus E, Grewal P, Liu L, Chang C, Bach N, Schiano TD. Massoumi H, et al. Transplantation. 2009 Sep 15;88(5):729-35. doi: 10.1097/TP.0b013e3181b2e0d1. Transplantation. 2009. PMID: 19741473
• Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.

  Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T. Ueda Y, et al. Transplantation. 2010 Sep 27;90(6):661-5. doi: 10.1097/TP.0b013e3181d2bfca. Transplantation. 2010. PMID: 20110853
• Practical management of liver transplant recipients for hepatitis C.

  Saab S, Busuttil RW. Saab S, et al. Minerva Chir. 2003 Aug;58(4):479-89. Minerva Chir. 2003. PMID: 14603160 Review.
• Therapy of hepatitis C: from empiricism to eradication.

  Pawlotsky JM. Pawlotsky JM. Hepatology. 2006 Feb;43(2 Suppl 1):S207-20. doi: 10.1002/hep.21064. Hepatology. 2006. PMID: 16447262 Review.